

IPCA PHARMA (NZ) PTY LIMITED
A.C.N.

DIRECTORS' REPORT

Your directors present the financial accounts of the company for the year ended 30 June 2018.

Directors

The names of the directors in office at the date of this report are:

Alakkudi Sundararaman
Murali Sarma

Principal Activities

The principal activities of the company in the course of the year were:

Reg'n & cloning of pharmaceutical products with Medsafe NZ.

No significant change in the nature of these activities occurred during the year.

Results

The net loss of the company for the financial year after providing for income tax amounted to \$10

Dividends paid or recommended

No dividends were paid or declared since the start of the financial year. No recommendation is made as to dividends.



IPCA PHARMA (NZ) PTY LIMITED

**PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 MARCH 2018**

	NOTE	2018 \$	2017 \$
EXPENSES			
Bank Charges		10	40
Retained Profits at April 1		1	41
		<hr/>	<hr/>
		9	(1)
		<hr/>	<hr/>
ACCUMULATED LOSSES		9	(1)
		<hr/>	<hr/>

9 ✓

The accompanying notes form part of these
financial statements
These statements are unaudited and should be read in
conjunction with the attached compilation report

IPCA PHARMA (NZ) PTY LIMITED

BALANCE SHEET
AS AT 31 MARCH 2018

	2018	2017
	NOTE \$	\$
CURRENT ASSETS		
Cash	210	220
TOTAL CURRENT ASSETS	<u>210</u>	<u>220</u>
NON-CURRENT ASSETS		
Intangibles	2,507	2,507
TOTAL NON-CURRENT ASSETS	<u>2,507</u>	<u>2,507</u>
TOTAL ASSETS	<u>2,717</u>	<u>2,727</u>
CURRENT LIABILITIES		
Other	2,639	2,639
TOTAL CURRENT LIABILITIES	<u>2,639</u>	<u>2,639</u>
NON-CURRENT LIABILITIES		
TOTAL NON-CURRENT LIABILITIES	<u>-</u>	<u>-</u>
TOTAL LIABILITIES	<u>2,639</u>	<u>2,639</u>
NET ASSETS	<u>78</u>	<u>88</u>
EQUITY		
Issued Capital	87	87
Accumulated Losses	9	(1)
TOTAL EQUITY	<u>78</u>	<u>88</u>

9

The accompanying notes form part of these
financial statements
These statements are unaudited and should be read in
conjunction with the attached compilation report

IPCA PHARMA (NZ) PTY LIMITED

**NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018**

NOTE 1 - STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

This financial report is a special purpose financial report prepared for use by the directors and member. The directors have determined that the company is not a reporting entity.

The financial report has been prepared in accordance with the requirements of the Corporations Law, and the following applicable Accounting Standards and other mandatory professional reporting requirements (Urgent Issues Group Consensus Views):

- AASB 1002: Events Occurring After Balance Date
- AASB 1018: Profit and Loss Accounts
- AASB 1025: Application of the Reporting Entity Concept and Other Amendments
- AASB 1031: Materiality
- AASB 1034: Information to be Disclosed in Financial Reports

No other applicable Accounting Standards or other mandatory professional reporting requirements (Urgent Issues Group Consensus Views) have been applied.

The statements have been prepared on an accruals basis. They are based on historical costs and do not take into account changing money values or, except where specifically stated, current valuations of non-current assets.

The following specific accounting policies, which are consistent with the previous period unless otherwise stated, have been adopted in the preparation of these statements:



These statements are unaudited and should be read in conjunction with the attached compilation report

IPCA PHARMA (NZ) PTY LIMITED

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018

9

**COMPILATION REPORT TO
IPCA PHARMA (NZ) PTY LIMITED**

We have compiled the accompanying special purpose financial statements of IPCA PHARMA (NZ) PTY LIMITED which comprise the balance sheet as at 31 ~~MARCH~~ 2018, profit and loss statement for the year then ended, a summary of significant accounting policies and other explanatory notes.

The specific purpose for which the special purpose financial report has been prepared is to provide information relating to the performance and financial position of the company that satisfies the information needs of the directors.

The responsibility of the directors

The directors are solely responsible for the information contained in the special purpose financial report and have determined that the basis of accounting used is appropriate to meet their needs and for the purpose for which the financial statements were prepared.

Our responsibility

On the basis of information provided by the directors, we have compiled the accompanying special purpose financial statements in accordance with the financial reporting framework described in Note 1 to the financial statements and APES 315: Compilation of Financial Information.

Our procedures use accounting expertise to collect, classify and summarise the financial information, which the directors provided, into a financial report. Our procedures do not include verification or validation procedures. No audit or review has been performed and accordingly no assurance is expressed.

The special purpose financial report was prepared exclusively for the directors. We do not accept responsibility to any other person for the content of the special purpose financial statements.

Name of Firm:

Pender & Associates Pty Ltd, Certified Practising Accountants

Name of Director:

Thomas Joseph Pender

Address:

Suite 4, Level 1, 474 Nepean Highway, Frankston, Victoria

Dated:

11th May 2018